PA-STRATUS-MATERIALS
25.6.2024 15:02:03 CEST | Business Wire | Press release
Stratus Materials Inc., a company focused on the development and commercialization of advanced cathode active materials (CAMs) for lithium-ion batteries, today announced that its first-generation LXMO CAM material has achieved a significant milestone associated with cycling durability in electric vehicle applications.
This month, LXMO-containing pouch cells surpassed 1,000 full depth-of-discharge cycles while maintaining greater than 80% of their initial capacity, a common goal across the EV battery industry. The 3rd party-built cells used standard cell and electrode designs, employing a natural graphite anode and an electrolyte of standard industry components, to work in conjunction with the Stratus cathode material. The cells in the test group maintained 82-86% of their initial capacity and are projected to exceed 1,200 cycles before reaching 80% of their initial capacities. At the same 1,000-cycle point, the average discharge voltage of the cells maintained approximately 97%, dropping only 0.1 V from their initial values. The excellent capacity and voltage stability of the cells surpass the energy retention of many commercial materials in use today.
Jay Whitacre, CEO & CTO of Stratus Materials (and Professor at Carnegie Mellon University), said: “These cells have been cycling for the last 10 months and clearly demonstrate that our proprietary materials are able to meet EV industry durability needs. To our knowledge this is the first time such minimal loss in cell voltage has been documented for this class of materials. The Stratus team looks forward to building upon these strong technical results as we improve, commercialize, and scale production in the coming quarters.”
Stratus products are in the lithium-rich, manganese-rich (LMR) category of cathode active materials. LMR cathodes have garnered significant interest in the Li-ion battery and EV industries due to several highly promising attributes including high energy density, low cost, and high safety. However, despite being in development around the world for over two decades, LMRs have not yet been commercially deployed because of several persistent technical challenges – primarily the voltage and capacity instability issues that Stratus Materials has largely overcome, as demonstrated by its latest results. With its continued technological progress, Stratus Materials is focused on enabling the first fully functional, LMR-class CAMs that are suitable for full-scale, commercial use.
Scott Pearson, President & CCO, added: “We are thrilled to show that our first-generation LXMO material can exceed this EV cell durability target while also delivering a set of highly compelling advantages versus incumbent CAMs. We expect that this proof point will be one of many that we will be offering to our industry partners and customers.”
Stratus is currently producing materials on its existing pre-pilot production line in Pittsburgh, Pennsylvania and has ongoing sampling efforts underway with many of the leading companies in the EV and EV battery industries. As previously announced, the company will be increasing its production capabilities from pre-pilot to pilot scale later in 2024.
ABOUT STRATUS MATERIALS
Stratus Materials (www.stratusmaterials.com) is a U.S. based company focused on the development and commercialization of next-generation cathode active materials (CAMs) for lithium-ion batteries. Our mission is to disrupt the CAM supply chain by offering materials with a game-changing combination of performance, safety, and cost. Stratus is primarily focusing its cobalt-free LXMOTM cathode products on light- and medium-duty electric vehicles and other applications with similar requirements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625022288/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 13:00:00 CEST | Press release
Award advances SOSA/CMOSS mission system ecosystem and informs future EW fielding decisions Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S
Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 13:00:00 CEST | Press release
Stablecoin settlement pilot sees record growth 50% quarter over quarter, reaching $7B run rate. Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means o
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release
OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
